News
Market and company headlines
ELVAll
Loading
05:00Oct 232 Stories
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495
TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $465 to $495.
Elevance Health (ELV) Stock Rallies As Q3 Results Tighten Margin Focus
Elevance Health just posted its Q3 2026 scorecard and the stock has shrugged off any hesitation. Shares are up 2.6% today to about US$445 even as earnings per share of US$6.30 sit below the prior quarter and net income is US$1.37b on more than US$51b of revenue. That is the sentiment clash investors need to watch. Short term traders are cheering the raised 2026 adjusted earnings guidance and the promise of at least 12% adjusted EPS growth in 2027, while the actual quarterly profit squeeze...
10:00-12:00Oct 222 Stories
UBS Maintains Buy on Elevance Health, Raises Price Target to $523
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.
07:00-10:00Oct 223 Stories
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449
Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:ELV) with a Equal-Weight and raises the price target from $404 to $449.
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455
RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and raises the price target from $424 to $455.
Barclays Maintains Overweight on Elevance Health, Raises Price Target to $472
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $469 to $472.
03:00-05:00Oct 222 Stories
ELV Q3 deep dive: Carelon expansion and Medicaid margin actions underpin raised outlook
Health insurance provider Elevance Health (NYSE:ELV) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $50.44 billion. Its non-GAAP profit of $6.99 per share was 48.9% above analysts’ consensus estimates.
Baird Maintains Neutral on Elevance Health, Raises Price Target to $406
Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $393 to $406.
00:00Oct 221 Story
14:00-00:00Oct 212 Stories
Elevance Health (ELV) Names Jeff Park Carelon President In Services Leadership Shift
Elevance Health (NYSE:ELV) has appointed Jeff Park as President of Carelon, its services-focused subsidiary. Park joins Elevance Health with a background in healthcare, pharmacy, and technology businesses, reflecting a services-focused leadership pick. The leadership change signals an effort to build out Carelon's integrated health solutions and sharpen execution across the services segment. Jeff Park's move into the Carelon president role is only one part of the broader Elevance Health...
Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run?
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
12:00-14:00Oct 213 Stories
Elevance (ELV) Q3 2026 Earnings Call Transcript
CEO Boudreaux raised full-year guidance on Medicaid improvements and Carelon momentum.
Elevance Health Inc. Q3 2026 Earnings Call Summary
Moby summary of Elevance Health Inc.'s Q3 2026 earnings call
What Elevance Health (ELV) Said on Its Q3 Earnings Call
Elevance Health (NYSE:ELV) raised its 2026 earnings outlook after reporting third-quarter adjusted diluted earnings per share of $6.99, exceeding the company’s expectations as Medicaid, Medicare Advantage and Individual ACA businesses all performed better than anticipated. President and CEO Gail Bo
10:00Oct 212 Stories
Elevance Health Posts Earnings Beat, Lifts Guidance. CFO Sees a ‘Clear Path’ to Growth.
Investors are continuing to watch how the insurer navigates costs in its Medicare Advantage and Medicaid portfolios.
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
08:00-10:00Oct 212 Stories
Elevance Health Shares Rise as Third-Quarter Earnings Beat Estimates and 2026 Guidance Increases
Elevance Health Inc. (NYSE:ELV) shares advanced 1.
Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
07:00Oct 211 Story
02:00Oct 201 Story
08:00Oct 191 Story
23:00Oct 181 Story
08:00-21:00Oct 162 Stories
3 US Dividend Stocks Worth Watching As Treasury Yields Climb
Bond yields are climbing, Washington is running a roughly $2t deficit on the way to about $40t of federal debt, and the government’s interest bill has crossed $1t a year. Income investors watching this know that higher Treasury payouts can tempt cash away from equities. This article looks at 3 large US dividend and value stocks exposed to these fiscal crosswinds and why they could still matter for your portfolio. The three stocks below are a sample. The full screen surfaced 13 more large US...
Unveiling Elevance Health (ELV) Q3 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
09:00Oct 151 Story
05:00Oct 121 Story
08:00-12:00Oct 102 Stories
Is Elevance Health (ELV) Undervalued After Its Recent Share Price Rally?
Elevance Health (ELV) has been on investors’ radar after a recent share price move, with the stock last closing at US$412.70. That shift now meets a business generating US$201.1b in annual revenue. Recent trading has been firm, with a 1-day share price return of 2.93% and a 7-day share price return of 6.80%. Elevance Health’s year-to-date share price return of 16.50% and 1-year total shareholder return of 19.16% point to momentum building despite a small 3-year total shareholder return...
Has Elevance Health (ELV) Earned Its Discount After Medicare Updates?
Elevance Health has delivered solid gains over the past year, and fresh product updates in its Medicare business keep the story moving. The open question for anyone looking at the stock now is whether that share price is adequately backed by the company’s earnings power. With a 19.2% return over the past year, Elevance Health has rewarded holders, which puts more focus on whether that move lines up with its earnings profile. The planned 2027 Medicare Advantage offerings aim to provide more...
06:00Oct 71 Story
08:00-11:00Oct 52 Stories
ELV or DHR: Which Is the Better Value Stock Right Now?
ELV vs. DHR: Which Stock Is the Better Value Option?
Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
INDIANAPOLIS, October 05, 2026--Elevance Health (NYSE: ELV) will release third quarter 2026 financial results on October 21, 2026 at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:
04:00-09:00Oct 22 Stories
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
How Much Downside Is Left In CVS Health Stock?
CVS Health (CVS) stock lost 12.7% in the past month without company news, and peers UnitedHealth, Cigna and Elevance Health fell too. The S&P 500 rose 0.6% over the same month. The shares now trade 22.5% below their 52-week high. How much further could CVS stock fall if the market itself turns down.
07:00-12:00Oct 12 Stories
Elevance Health (ELV): Conviction Pays Off as Underwriting Disciplines Stabilize Margins
Cambiar Opportunity Fund, managed by Cambiar Investors, published its Q2 2026 investor letter. The letter can be downloaded here. U.S. equity markets experienced a significant rebound in Q2, with the S&P 500 rising 15.2% and the Russell 2000 up 21.5%. Growth stocks outperformed value, although value retained a year-to-date lead. The market’s rise was fueled […]
Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
INDIANAPOLIS, October 01, 2026--Elevance Health (NYSE: ELV) announced today that its affiliated health plans will offer 2027 Medicare Advantage plans designed to help members navigate healthcare more confidently through meaningful choice, simpler benefit experiences and personalized support that reflects individual health needs.
11:00-15:00Sep 302 Stories
Elevance cracks down on hospital billing for off-campus care
The insurer said it’s trying to restrict hospitals from charging higher rates for services at off-campus outpatient departments. Hospital groups say the reimbursement cuts could threaten access to care.
Elevance Health's Quarterly Earnings Preview: What You Need to Know
Elevance Health is scheduled to report its third-quarter results soon, and analysts expect a double-digit earnings decline.
14:00Sep 291 Story
05:00-08:00Sep 222 Stories
How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet
Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.
'Vance-Led Task Force Set to Remove 760,000 Allegedly Fraudulent Obamacare Enrollments' - WSJ Exclusive
https://www.wsj.com/politics/policy/vance-led-task-force-set-to-remove-760-000-allegedly-fraudulent-obamacare-enrollments-0fbb72d7
02:00-17:00Sep 202 Stories
Tracking William Nygren's Harris Associates Portfolio - Q2 2026 Update
Harris Associates' 13F portfolio rose to $75.42B in Q2 2026, with 30 core positions exceeding 1.25% each. Read more on the portfolio here.
Elevance Health (ELV) Stock May Be Below Fair Value As Guidance Was Reaffirmed
Elevance Health has delivered a 1 year gain that puts the stock firmly on investors' radar, and the latest reaffirmed earnings outlook has only sharpened the focus on what you are paying for each dollar of profit. With the price around US$410.95 at the last close, the key issue now is whether that tag lines up with the insurer's earnings power. The stock is up 33.6% over the past year, which raises the question of whether that move is grounded in its underlying earnings profile. Management...
03:00Sep 181 Story
04:00-10:00Sep 162 Stories
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
Baron Health Care Fund Q2 2026 Portfolio Activity
During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43.
11:00Sep 151 Story
09:00Sep 111 Story
15:00Sep 102 Stories
Should You Buy Elevance Health Stock For The Margin It Lost?
Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.
Thursday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
12:00-14:00Sep 102 Stories
UnitedHealth Reshapes Florida WellMed Operations With TPG Deal
UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
07:00-11:00Sep 102 Stories
Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation
Elevance Health shares are jumping Thursday after the company reaffirmed its FY26 earnings guidance ahead of a series of investor meetings.
Elevance Health Inc's Dividend Analysis
Elevance Health Inc (NYSE:ELV) recently announced a total dividend of $1.72 per share, with the ex-dividend date set for 2026-09-10. For investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the upcoming payment. As investors look forward to this next distribution, the spotlight also shines on the company's dividend history, yield, and growth rates.